Madrigal Pharmaceuticals, Inc. (MDGL)

NASDAQ: MDGL · IEX Real-Time Price · USD
267.04
+8.23 (3.18%)
At close: Mar 28, 2024, 4:00 PM
268.21
+1.17 (0.44%)
After-hours: Mar 28, 2024, 7:59 PM EDT
3.18%
Market Cap 5.52B
Revenue (ttm) n/a
Net Income (ttm) -373.63M
Shares Out 19.90M
EPS (ttm) -19.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 435,650
Open 258.54
Previous Close 258.81
Day's Range 254.75 - 268.22
52-Week Range 119.76 - 322.67
Beta -0.48
Analysts Strong Buy
Price Target 375.90 (+40.77%)
Earnings Date May 7, 2024

About MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 376
Stock Exchange NASDAQ
Ticker Symbol MDGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for MDGL stock is "Strong Buy." The 12-month stock price forecast is $375.9, which is an increase of 40.77% from the latest price.

Price Target
$375.9
(40.77% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatit...

10 days ago - GlobeNewsWire

Madrigal Pharmaceuticals Announces Proposed Public Offering

CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatit...

10 days ago - GlobeNewsWire

Madrigal Pharma surges on FDA nod to first drug for fatty liver disease NASH

Shares of Madrigal Pharmaceuticals jumped about 30% on Friday after its oral drug became the first treatment to win the health regulator's nod for a fatty liver disease known as non-alcoholic steatohe...

14 days ago - Reuters

FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease

The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are still trying to break into.

14 days ago - CNBC

Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH

Madrigal Pharmaceuticals Inc. on Thursday received the first Food and Drug Administration approval for a drug designed to treat a severe liver disease known as MASH.

14 days ago - Market Watch

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatiti...

14 days ago - GlobeNewsWire

Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle

Madrigal Pharmaceuticals' drug became the first to win regulatory approval to treat a serious type of fatty liver disease formerly known as non-alcoholic steatohepatitis (NASH) as the race to tap a mu...

14 days ago - Reuters

US FDA approves first drug for fatty liver disease NASH

The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition and opening up a ...

14 days ago - Reuters

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati...

22 days ago - GlobeNewsWire

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

4 weeks ago - GlobeNewsWire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

4 weeks ago - GlobeNewsWire

Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

CONSHOHOCKEN, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

2 months ago - GlobeNewsWire

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

CONSHOHOCKEN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

3 months ago - GlobeNewsWire

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati...

3 months ago - GlobeNewsWire

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

4 months ago - GlobeNewsWire

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

4 months ago - GlobeNewsWire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

CONSHOHOCKEN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

5 months ago - GlobeNewsWire

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepat...

6 months ago - GlobeNewsWire

Medtech Makers Are the Real Losers From Obesity Drugs

Shares of companies that treat everything from Type 2 diabetes to sleep apnea have been sinking since new weight-loss medications skyrocketed.

Other symbols: DXCMINSPPODDRMDTNDM
6 months ago - Barrons

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati...

7 months ago - GlobeNewsWire

Madrigal Pharmaceuticals shares fall after new CEO named

Shares of Madrigal Pharmaceuticals Inc. MDGL, +2.91% fell more than 7% premarket on Monday after the company appointed Bill Sibold, a former Sanofi SNY, +1.06% executive, as its new CEO. Sibold succee...

7 months ago - Market Watch

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati...

7 months ago - GlobeNewsWire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

CONSHOHOCKEN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

8 months ago - GlobeNewsWire

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

CONSHOHOCKEN, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...

9 months ago - GlobeNewsWire

Madrigal Pharmaceuticals' stock up 5% as company starts rolling submission for FDA approval of NASH treatment

Madrigal Pharmaceuticals Inc.'s stock MDGL, +5.00% rose 5% Friday after the company said it has started a rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking ...

9 months ago - Market Watch